Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...

Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF BoardSTUDIO CITY, Calif., Nov. 26 ...

Richard’s journey with multiple myeloma began in late 2020 with unrelenting back pain, fatigue, and breathing difficulties.

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

Experience convenient blood cancer treatment close to home. Find out how this unique partnership brings autologous stem cell ...